

MALARIA AND SOME POLYOMAVIRUSES (SV40, BK, JC, AND MERKEL CELL VIRUSES)

VOLUME 104

This publication represents the views and expert
opinions of an IARC Working Group on the
Evaluation of Carcinogenic Risks to Humans,
which met in Lyon, 7-14 February 2012

LYON, FRANCE - 2014

IARC MONOGRAPHS
ON THE EVALUATION
OF CARCINOGENIC RISKS
TO HUMANS

LIST OF PARTICIPANTS

Members ¹

Jürgen C. Becker [unable to attend]

Department of Dermatology
Medical University of Graz
Graz
Austria

Janet S. Butel

Department of Molecular Virology
and Microbiology
Baylor College of Medicine
Houston, TX
USA

Maria-Teresa Bejarano

Center for Infectious Medicine
Karolinska Institute
Stockholm
Sweden

Pierre Coursaget

Infections and Public Health Unit
University François Rabelais
Tours
France

¹ Working Group Members and Invited Specialists serve in their individual capacities as scientists and not as representatives of their government or any organization with which they are affiliated. Affiliations are provided for identification purposes only. Invited Specialists do not serve as meeting chair or subgroup chair, draft text that pertains to the description or interpretation of cancer data, or participate in the evaluations.

Each participant was asked to disclose pertinent research, employment, and financial interests. Current financial interests and research and employment interests during the past 4 years or anticipated in the future are identified here. Minor pertinent interests are not listed and include stock valued at no more than US\$1000 overall, grants that provide no more than 5% of the research budget of the expert's organization and that do not support the expert's research or position, and consulting or speaking on matters not before a court or government agency that does not exceed 2% of total professional time or compensation. All grants that support the expert's research or position and all consulting or speaking on behalf of an interested party on matters before a court or government agency are listed as significant pertinent interests.

Tina Dalianis (Subgroup Chair, Exposure Data)

Department of Oncology–Pathology
Karolinska Institute
Stockholm
Sweden

Ajay Goel [not present for evaluations]

Baylor Research Institute and
Charles A. Sammons Cancer Center
Baylor University Medical Center
Dallas, TX
USA

Andrew Darnton [unable to attend]

Science, Engineering and Analysis (CSEAD)
Health and Safety Executive
Bootle
England

Jennifer Gordon

Center for Neurovirology
Temple University School of Medicine
Philadelphia, PA
USA

Silvia de Sanjosé (Subgroup Chair, Cancer in Humans)

Cancer Epidemiology Research Programme
Catalan Institute of Oncology
Barcelona
Spain

Sam M. Mbulaiteye

Division of Cancer Epidemiology and
Genetics
National Cancer Institute
Rockville, MD
USA

Joakim Dillner²

Department of Medical Epidemiology and
Biostatistics
Karolinska Institute
Stockholm
Sweden

Robert Newton (Meeting Chair)

Department of Health Sciences
University of York
Heslington
England

Eric A. Engels

Division of Cancer Epidemiology & Genetics
National Cancer Institute
Bethesda, MD
USA

Michael Pawlita (Subgroup Chair, Mechanistic and Other Relevant Data)

Research Program Infection and Cancer
German Cancer Research Centre (DKFZ)
Heidelberg
Germany

² Dr Dillner was a Visiting Scientist at the IARC at the time of the meeting.

Rosemary Rochford

Department of Microbiology and
Immunology
SUNY Upstate Medical University
Syracuse, NY
USA

Marita Troye-Blomberg

Wenner-Gren Institute
Stockholm University
Stockholm
Sweden

Dana E. Rollison

Department of Cancer Epidemiology
H. Lee Moffitt Cancer Center and
Research Institute
Tampa, FL
USA

Raphael Viscidi

Department of Molecular Microbiology
and Immunology
The Johns Hopkins Hospital
Baltimore, MD
USA

Ronit Sarid

The Mina & Everard Goodman Faculty
of Life Sciences
Bar-Ilan University
Ramat-Gan
Israel

*Mats Wahlgren*³ [*only present for part of the
evaluations*]

Department of Microbiology, Tumour and
Cell Biology
Karolinska Institute
Stockholm
Sweden

*Keerti V. Shah (Subgroup Chair, Cancer in
Experimental Animals)*

Department of Molecular Microbiology
and Immunology
Johns Hopkins School of Public Health
Baltimore, MD
USA

Axel zur Hausen

GROW-School for Oncology &
Developmental Biology
Maastricht University Medical Center
Maastricht
The Netherlands

Peter Odada Sumba

Centre For Global Health and Research
Kenya Medical Research Institute (KEMRI)
Kisumu
Kenya

³ Mats Wahlgren holds a patent in the USA on a malaria vaccine.

Invited Specialists

*Christopher B. Buck*⁴

Tumor Virus Molecular Biology Section
National Cancer Institute
Bethesda, MD
USA

*Yuan Chang*⁵

Cancer Institute
University of Pittsburgh
Pittsburgh, PA
USA

*Mauro Tognon*⁶

Faculty of Medicine and Surgery
University of Ferrara
Ferrara
Italy

Representatives

Donald G. Blair

Cancer Etiology Branch
Division of Cancer Biology
National Cancer Institute
Rockville, MD
USA

Observers⁷

*Edith Y. Roset-Bahmanyar*⁸ [did not attend]

GlaxoSmithKline Biologicals
Wavre
Belgium

⁴ Christopher Buck is a co-inventor on two current patent applications and one pending patent application covering technologies related to development of prophylactic vaccines against Merkel cell polyomaviruses, human polyomaviruses 6 and 7 (HPyV6 and HPyV7), JC and BK polyomaviruses.

⁵ Yuan Chang's laboratory identified Merkel cell polyomavirus in 2008 and the University of Pittsburgh has USA and European patent coverage for methods to diagnose and immunize against the virus causing human Merkel cell carcinoma.

⁶ Mauro Tognon is a co-inventor of one pending patent application for an indirect ELISA assay for the detection of SV40-specific large T antigen antibodies.

⁷ Each Observer agreed to respect the Guidelines for Observers at *IARC Monographs* meetings. Observers did not serve as meeting chair or subgroup chair, draft any part of a Monograph, or participate in the evaluations. They also agreed not to contact participants before the meeting, not to lobby them at any time, not to send them written materials, and not to offer them meals or other favours. IARC asked and reminded Working Group Members to report any contact or attempt to influence that they may have encountered, either before or during the meeting.

⁸ Edith Roset Bahmanyar is employed by GlaxoSmithKline Biologicals, Belgium. She is involved in phase IV studies for the candidate RTS,S/AS vaccine.

IARC Secretariat

Rosita Accardi-Gheit
Robert Baan (*Rapporteur, Mechanistic and Other Relevant Data*)
Lamia Benbrahim-Tallaa (*Rapporteur, Cancer in Experimental Animals*)
Véronique Bouvard (*Responsible Officer; Rapporteur, Mechanistic and Other Relevant Data*)
Gary Clifford
Jean-Damien Combes
Isabelle Deltour
Catherine De Martel
Fatiha El Ghissassi (*Rapporteur, Exposure Data*)
Silvia Franceschi
Tarik Gheit
Yann Grosse (*Rapporteur, Cancer in Experimental Animals*)
Neela Guha (*Rapporteur, Cancer in Humans*)
Michelle Iannacone
Béatrice Lauby-Secretan (*Rapporteur, Exposure Data*)
Martyn Plummer
Kurt Straif (*Head of Programme*)
Bakary Sylla
Maria Timofeeva
Massimo Tommasino
Salvatore Vaccarella
Magdalena Wozniak

Post-meeting Assistance

Karen Müller (*Scientific Editor for Volume 104*)
Heidi Mattock (*Scientific Editor, Malaria*)

Production Team

Elisabeth Elbers
Dorothy Russell
Arthur Bouvard (*Reproduction of Graphics*)

Administrative Assistance

Sandrine Egraz
Michel Javin
Brigitte Kajo
Annick Leroux
Helene Lorenzen-Augros

